

1 ABSTRACT

2  
3 The inventors propose a combination of an HMG-CoA reductase inhibitor (also  
4 referred to as "HMG-CoA inhibitor(s)"), and COX-2 inhibitor for the treatment of cancer  
5 especially prostate cancer and a method of treatment of cancer by that combination,  
6 especially prostate cancer. The inventors propose a combination of an HMG-CoA  
7 reductase inhibitor, COX-2 inhibitor, and glutathione pathway enhancing and detoxifying  
8 compound, particularly cystine, for the treatment of cancer especially prostate cancer and  
9 a method of treatment of cancer by that combination, especially prostate cancer. Also  
10 contemplated is the addition of lipoic acid and compounds to maintain adequate levels of  
11 Selenium, Vitamin C and Vitamin E. Based on the clinical results of retardation, but not  
12 cure of cancer, the combination has the characteristic of sufficiently interfering with  
13 replication and apparently restoring the immune system capacity to manage cancer.